SOHO 2021 | HemOnc vaccines: an update
Nina Shah, MD, of the University of California, San Francisco, CA, talks on the latest regarding the use of cancer vaccines as a viable treatment method. Dr Nina sheds light on the Phase II BMT CTN 1401 trial (NCT02728102) investigating a dendritic cell/myeloma fusion vaccine for multiple myeloma, based on the concept of immune reconstitution. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Nina Shah, MD, has received research funding from Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar and Precision Biosciences; and has participated in an advisory role with GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides and CSL Behring.
